Hengrui Therapeutics, Inc.

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show

A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dat

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

The past decade has seen an unprecedented rise in Immuno-oncology therapies, driven by the success of immune checkpoint inhibitors (ICIs), such as PD-(L)1 antibody therapies. In 2021, the ICI market a